Summary by Futu AI
Senti Biosciences, a biotechnology company specializing in gene circuit technologies, reported a net loss of $12.1 million for the first quarter of 2024, compared to a net loss of $18.7 million for the same period in 2023. The company's cash and cash equivalents stood at $23.7 million as of March 31, 2024, down from $35.9 million at the end of the previous year. Operating expenses for the quarter were $16.3 million, with research and development costs accounting for $8.8 million of that total. Senti Biosciences has entered into various agreements, including a collaboration with BlueRock Therapeutics and a transaction with GeneFab LLC, which provided the company with capital in the form of a note receivable and rights to future manufacturing and research activities. The company also subleased its Alameda...Show More